Presentation is loading. Please wait.

Presentation is loading. Please wait.

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Published byErik de Veen Modified over 5 years ago

Similar presentations

Presentation on theme: "Amy S. Paller, MD, Elaine C. Siegfried, MD, David M"— Presentation transcript:

1 Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis 
Amy S. Paller, MD, Elaine C. Siegfried, MD, David M. Pariser, MD, Kara Creamer Rice, MS, Mona Trivedi, MD, Jan Iles, MD, David H. Collier, MD, Greg Kricorian, MD, Richard G. Langley, MD  Journal of the American Academy of Dermatology  Volume 74, Issue 2, Pages e3 (February 2016) DOI: /j.jaad Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Plaque psoriasis, patient disposition. OLE, Open-label extension. Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Plaque psoriasis, efficacy outcomes in children and adolescents treated with etanercept. The percentage of patients with 75% improvement in Psoriasis Area and Severity Index score (PASI 75) (A), 90% improvement in Psoriasis Area and Severity Index score (PASI 90) (B), and static physician global assessment (sPGA) status of clear/almost clear (score 0/1) (C) from week 96 through week 264 is shown. The number of patients with available data is shown below each graph. Data are reported as observed, without imputation for missing data. Error bars represent 95% confidence interval (CI). Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

4 Supplemental Fig 1 Study schema. aDuring the double-blind treatment phase, patients were randomized (1:1) to etanercept or placebo weekly. After week 4, patients could enter an escape group and receive open-label etanercept through week 12 if their Psoriasis Area and Severity Index (PASI) score either increased by >50% over baseline and by a minimum of 4 points at 1 visit or increased by >25% and by a minimum of 4 points at each of 2 consecutive visits. bAll patients, including those who entered the escape group during weeks 4 through 12, received open-label etanercept. Patients who did not achieve a 50% improvement in PASI score (PASI 50) at week 24 or a 75% improvement in PASI score (PASI 75) at week 36 could discontinue the study or add topical standard-of-care therapy and continue to receive open-label etanercept until week 48. cAt week 36, patients with a PASI 50 at week 24 or PASI 75 at week 36 were randomized (1:1) to etanercept or placebo. Patients who lost their PASI 75 response resumed open-label etanercept through week 48. EOS, End of study; OLE, open-label extension. Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

5 Supplemental Fig 2 The 75% improvement in Psoriasis Area and Severity Index score (PASI 75) and 90% improvement in Psoriasis Area and Severity Index score (PASI 90) responses in patients who developed anti-etanercept antibodies. The percentage of patients who achieved PASI 75 (A) and PASI 90 (B) response from baseline of the parent study is shown for patients who developed anti-etanercept antibodies (open circles) and all patients (closed diamonds). No patient developed neutralizing antibodies. CI, Confidence interval. Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

6 Supplemental Fig 3 The percentage of patients categorized as healthy weight (body mass index [BMI] 5th-84th percentile∗; open diamonds), overweight (BMI 85th-94th percentile; gray squares), and obese (BMI ≥95th percentile; black triangles) who achieved a 75% improvement in Psoriasis Area and Severity Index score (PASI 75) response from baseline of the parent study. ∗Barlow SE; Expert Committee. Expert Committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007;120(Suppl):S CI, Confidence interval. Journal of the American Academy of Dermatology  , e3DOI: ( /j.jaad ) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Amy S. Paller, MD, Elaine C. Siegfried, MD, David M"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis  Alan Menter,
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Psoriasis and suicidality: A systematic review and meta-analysis

Psoriasis and suicidality: A systematic review and meta-analysis
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional.
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

Similar presentations

Ads by Google